Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5281584
Max Phase: Preclinical
Molecular Formula: C23H32N6O
Molecular Weight: 408.55
Associated Items:
ID: ALA5281584
Max Phase: Preclinical
Molecular Formula: C23H32N6O
Molecular Weight: 408.55
Associated Items:
Canonical SMILES: Cc1nn(C)c2ccc(N(CC3CCCC3)C(=O)NCCCn3cncc3C)cc12
Standard InChI: InChI=1S/C23H32N6O/c1-17-14-24-16-28(17)12-6-11-25-23(30)29(15-19-7-4-5-8-19)20-9-10-22-21(13-20)18(2)26-27(22)3/h9-10,13-14,16,19H,4-8,11-12,15H2,1-3H3,(H,25,30)
Standard InChI Key: SVYLHTBEBXIUEE-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 408.55 | Molecular Weight (Monoisotopic): 408.2638 | AlogP: 4.18 | #Rotatable Bonds: 7 |
Polar Surface Area: 67.98 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.33 | CX LogP: 2.38 | CX LogD: 2.20 |
Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.60 | Np Likeness Score: -1.73 |
1. Van Manh N, Hoang VH, Ngo VTH, Kang S, Jeong JJ, Ha HJ, Kim H, Kim YH, Ann J, Lee J.. (2022) Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents., 244 [PMID:36265279] [10.1016/j.ejmech.2022.114837] |
Source(1):